Navigation Links
MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
Date:7/15/2010

ue of Arthritis & Rheumatism(1) and the June 2010 issue of Journal of Molecular Biology(2).  In addition, progress with respect to the company's DART platform has been presented at several recent scientific conferences.

This platform has broad potential applications for developing novel therapeutics.  These include approaches to signaling immune-mediated cells to treat autoimmune disorders, the redirecting of immune cells to kill tumors and inhibition of different signaling pathways required for tumor growth.  Furthermore, this technology is especially promising for treating certain infectious diseases, as it enables the targeting of two serotypes of a pathogen with a single molecule.

"We have made tremendous progress on our DART platform," said Dr. Scott Koenig, President and CEO.  "We believe we have the ability to create highly potent DART-based therapeutics and the funding from NIH will help us move forward two product candidates based on our proprietary platform."

Background on DART

MacroGenics' DART technology is focused on dual specificity antibody-based therapeutic proteins, which enables the creation of highly stable, recombinant molecules that can simultaneously target two different antigens. DART therapeutics can accommodate virtually any variable region sequence in a "plug-and-play" fashion, are potent, and have very favorable manufacturing properties.  To date, the company has engineered over 60 different DART molecules and has completed multiple in vitro and in vivo proof-of-concept studies with several prototypes.  The company has been able to produce DART molecules in both bacterial and mammalian expression systems. DARTs also have been engineered with an Fc domain, which confers them with additional pr
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MacroGenics Raises $25M in Series D-2 Financing
2. MacroGenics Appoints New Vice President of Business Development
3. Paulo F. Costa Joins MacroGenics Board of Directors
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Washington D.C. (PRWEB) September 22, 2014 ... and Georgetown President John DeGioia on Friday renewed ... understanding for an additional five years to expand ... security, biosecurity, nonproliferation and global climate, energy and ... expansion of an MOU originally signed in December ...
(Date:9/22/2014)... 2014 Topical BioMedics, Inc., is celebrating ... end their suffering, restoring hope an quality of life ... only possible because of the innovative cellular biomedicines research ... a reality. , The company was founded in ... Paradise (president, chief of research, and Topricin inventor), Aurora ...
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "Global and Chinese Microcrystalline Cellulose Industry Report ... The Global and Chinese Microcrystalline Cellulose Industry Report 2014 ... state of the global microcrystalline cellulose industry with a ... provides a basic overview of the industry including definitions, ...
(Date:9/22/2014)... -- Neogen Corporation (Nasdaq: NEOG ) announced today ... 2015 fiscal year, which ended Aug. 31, was $8,883,000 ... $7,839,000 in the first quarter of last year. Adjusted ... earnings per share in the current quarter were $0.24, ... quarter revenues increased 15% to $67,599,000, from the previous ...
Breaking Biology Technology:Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7
... InterMune, Inc. (Nasdaq: ITMN ) today announced that the ... the New Drug Application (NDA) for Esbriet™ (pirfenidone) for the treatment of ... , , , ... is issued by the FDA,s Center for Drug Evaluation and Research when ...
... , May 4 Romark Laboratories announced results from ... nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.  Study ... late breaking forum of the American Gastroenterological Association Institute (AGA Institute) ... , , , ...
... Microfluidics International Corporation (OTC Bulletin Board: MFLU) announced today the Company will release ... 8:30am ET . , , , ... , , , ... Executive Officer, and Peter F. Byczko , Vice President of Finance and Chief ...
Cached Biology Technology:InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010 2Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010 3
(Date:9/22/2014)... As genetic sequencing technologies continue to evolve rapidly, ... need to establish appropriate policies and regulatory frameworks to ... A special policy issue of the Journal of ... edited by experts with the Center for Medical Ethics ... policy makers the tools to jumpstart this process. ...
(Date:9/22/2014)... the Society of Environmental Toxicology and Chemistry (SETAC) held ... prioritize the scientific research needed to understand the risks ... environment. The effort was extended, and results were ... international journal, Integrated Environmental Assessment and Management ... podcast interviewing the lead author of the study, Murray ...
(Date:9/22/2014)... be much more useful in homes, if they could ... the world with cameras and lasers, which have difficulty ... hidden in clutter. A complementary way robots can "sense" ... small ultra-high frequency radio-frequency identification (UHF RFID) tags. Inexpensive ... RFID-equipped robot to search a room for the correct ...
Breaking Biology News(10 mins):Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3Priorities for research on pharmaceutical and personal care products in the environment 2New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3
... molecule, a measly angstrom's difference in diameter is a ... a sleek, water-molecule-sized sports car, say scientists at the ... in aquaporins, a class of proteins that form trans-membrane ... They allow for water movement between the cell and ...
... of a piece of the spike-shaped protein that the SARS ... stages of infection. The structure, which shows how the spike ... about how the virus infects cells. The information could also ... exploited by novel antiviral drugs or vaccines. , The ...
... charged lipids and DNA molecules have created a "cookbook" ... will assist doctors and clinicians in the safe and ... the Aug. 9 issue of the Proceedings of the ... careful, comprehensive study to see how negatively charged lipids ...
Cached Biology News:Cells direct membrane traffic by channel width 2Learning how SARS spikes its quarry 2Learning how SARS spikes its quarry 3'Cookbook recipes' would cure disease with nontoxic DNA delivery systems 2
... enzyme-activity assay based on measurenment of enzyme ... antibody coated microtiter plate. The procedure includes ... or controls, 2nd enzyme reaction) separated ... intended for the determination of human enzymaticaly ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
Biology Products: